



February 25, 2015

## **Alder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial and Operating Results**

BOTHELL, Wash., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that it will report its fourth quarter and full year 2014 financial and operating results after the close of U.S. financial markets on Wednesday, March 4, 2015. Alder management will host a conference call and live audio webcast at 5:00 p.m. EST the same day.

The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers, and providing conference ID number 81724486. The webcast will be broadcast live on the investors section of Alder's website at [www.alderbio.com](http://www.alderbio.com) and will be available for replay following the call for 30 days.

### **About Alder BioPharmaceuticals**

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's ALD403 inhibits a well-validated molecule shown to trigger migraine attacks, calcitonin gene-related peptide (CGRP), and is now undergoing clinical testing. Alder advanced ALD403 into a Phase 2b trial for the treatment of chronic migraines and plans to initiate a Phase 2b trial for the treatment of frequent episodic migraines in the first half of 2015. Alder's second program, Clazakizumab, previously known as ALD518, is designed to block the pro-inflammatory cytokine IL-6 and has completed a Phase 2b clinical trial. For more information, please visit <http://www.alderbio.com>.

### **Forward-Looking Statements**

This press release contains forward-looking statements, including statements regarding the further development of ALD403, the initiation of future clinical trials and the potential of ALD403 and Clazakizumab to address the unmet medical needs of patients. All forward-looking statements included in this press release are based on our management's beliefs and assumptions and on information currently available to our management, and we assume no obligation to update any such forward-looking statements. Any or all of our forward-looking statements in this document may turn out to be wrong and actual events or results may differ materially. Our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks, uncertainties and other factors. In evaluating these statements, you should specifically consider various factors, including the risks outlined under the caption "Risk Factors" set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 filed with the Securities and Exchange Commission (SEC) and other reports and filings we will make with the SEC from time to time. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

CONTACT: Media Contacts:

David Schull or Lena Evans

Russo Partners

(212) 845-4271

(212) 845-4262

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

[lena.evans@russopartnersllc.com](mailto:lena.evans@russopartnersllc.com)

Investor Relations Contact:

Sarah McCabe

Stern Investor Relations, Inc.

(212) 362-1200

sarah@sternir.com